You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Pfizer’s Ibrance flunks early breast cancer trial

Pfizer’s oral CDK4/6 inhibitor Ibrance has failed to meet the primary endpoint of improved invasive disease-free survival (iDFS) in early breast cancer, nixing its chances in the adjuvant setting.